Dinesh V. Patel, President and CEO of Protagonist Therapeutics (NASDAQ:PTGX), sold approximately $7.5 million worth of common stock on May 12, 2026, following the exercise of stock options. The transactions were executed under a Rule 10b5-1 trading plan adopted on January 30, 2026.
Mr. Patel sold 75,000 shares at a weighted average price of $100.12 per share, with prices ranging from $98.83 to $103.50. Post-sale, he directly owns 523,478 shares. The total sales value was $7,509,000.
The sale occurred as PTGX stock trades near its 52-week high of $107.84, following a 138% return over the past year. According to Bond.az analysis, the stock appears overvalued relative to its Fair Value.
